BiotechTube
KeraMed

KeraMed

Irvine, United States· Est.
keramed.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.8M

Overview

KeraMed is a specialized ophthalmology device company developing the KeraKlear Artificial Cornea, a novel implant for synthetic lamellar keratoplasty. The device is designed for implantation through a small 3.5mm incision, aiming to replace opacified corneal tissue with minimal tissue removal. While the product has achieved CE Mark certification and initial clinical use internationally, it remains an investigational device in the United States, limited to clinical studies. The company's strategy centers on advancing this technology for conditions like keratoconus, corneal scars, and failed transplants.

OphthalmologyCorneal Diseases

Technology Platform

Minimally invasive corneal implant platform centered on the KeraKlear, a foldable, non-penetrating artificial cornea designed for implantation into a femtosecond laser-created corneal pocket.

Funding History

1
Total raised:$2.8M
Seed$2.8M

Opportunities

The KeraKlear addresses a critical unmet need in regions with donor cornea shortages and for patients who are not candidates for traditional transplant.
Its minimally invasive profile could drive surgeon adoption by offering faster procedures and recovery compared to full-thickness transplants.
Successful FDA approval would open the large U.S.
market and validate the technology for global expansion.

Risk Factors

The primary risk is regulatory; the device remains investigational in the U.S., and FDA approval is not guaranteed.
Clinical adoption by surgeons accustomed to established techniques may be slow.
The company faces competition from other artificial corneas, bioengineered tissues, and improving donor transplant methods.

Competitive Landscape

KeraMed competes in the artificial cornea (keratoprosthesis) market against devices like the Boston Keratoprosthesis and the Osteo-Odonto-Keratoprosthesis. It differentiates through its non-penetrating, lamellar approach. Broader competition includes donor corneal transplants and emerging regenerative medicine approaches. Its key challenge is to prove superior safety, efficacy, and ease-of-use versus these established and evolving alternatives.

More companies in Regenerative Medicine →More companies in United States →